David Slosky

3.6k total citations
18 papers, 336 citations indexed

About

David Slosky is a scholar working on Molecular Biology, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, David Slosky has authored 18 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in David Slosky's work include Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Cardiac tumors and thrombi (3 papers) and Peptidase Inhibition and Analysis (3 papers). David Slosky is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Cardiac tumors and thrombi (3 papers) and Peptidase Inhibition and Analysis (3 papers). David Slosky collaborates with scholars based in United States, Japan and France. David Slosky's co-authors include Herbert S. Schwartz, Takashi Ando, Justin Cates, Heather A. Cole, Jonathan G. Schoenecker, Javid J. Moslehi, James K. Todd, Robert F. Cornell, Daniel J. Lenihan and Toni K. Choueiri and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David Slosky

17 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Slosky United States 10 135 126 108 89 47 18 336
Edelmiro Regañón Spain 13 159 1.2× 86 0.7× 83 0.8× 91 1.0× 86 1.8× 25 427
Virtudes Vila Spain 13 167 1.2× 88 0.7× 103 1.0× 110 1.2× 90 1.9× 32 491
P. Reinecke Germany 10 139 1.0× 83 0.7× 70 0.6× 76 0.9× 37 0.8× 35 418
Simone Mangan Australia 5 200 1.5× 83 0.7× 82 0.8× 99 1.1× 46 1.0× 7 451
Dìlek Dìnçol Türkiye 10 73 0.5× 143 1.1× 54 0.5× 105 1.2× 46 1.0× 28 394
Paraskevi Roussou Greece 13 100 0.7× 138 1.1× 164 1.5× 75 0.8× 28 0.6× 21 528
Katerina Sfiridaki Greece 11 107 0.8× 94 0.7× 40 0.4× 146 1.6× 24 0.5× 17 376
Weihui Shentu China 10 97 0.7× 48 0.4× 104 1.0× 55 0.6× 16 0.3× 29 364
F. Majois Belgium 9 56 0.4× 224 1.8× 55 0.5× 69 0.8× 59 1.3× 28 350
Νικόλαος Παναγόπουλος Greece 14 94 0.7× 93 0.7× 56 0.5× 211 2.4× 64 1.4× 29 445

Countries citing papers authored by David Slosky

Since Specialization
Citations

This map shows the geographic impact of David Slosky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Slosky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Slosky more than expected).

Fields of papers citing papers by David Slosky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Slosky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Slosky. The network helps show where David Slosky may publish in the future.

Co-authorship network of co-authors of David Slosky

This figure shows the co-authorship network connecting the top 25 collaborators of David Slosky. A scholar is included among the top collaborators of David Slosky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Slosky. David Slosky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Holmes, Benjamin, Shi Huang, Asad A. Aboud, et al.. (2020). Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. EP Europace. 22(8). 1216–1223. 32 indexed citations
2.
Kim, Eun Jeong, Benjamin Holmes, Shi Huang, et al.. (2019). DOES AN IMPLANTABLE DEFIBRILLATOR ALTER OUTCOMES IN PATIENTS WITH CARDIAC AMYLOIDOSIS?. Journal of the American College of Cardiology. 73(9). 837–837. 5 indexed citations
3.
Oke, Oluchi, Tarsheen Sethi, Stacey Goodman, et al.. (2017). Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation. 23(9). 1473–1477. 6 indexed citations
4.
Bloomer, Tyler, Matthew R. Alexander, Daniel J. Lenihan, et al.. (2017). MYOCARDITIS AND RHABDOMYOLYSIS INCIDENCE WITH IMMUNE CHECKPOINT INHIBITORS. Journal of the American College of Cardiology. 69(11). 943–943. 2 indexed citations
5.
Rubinstein, Samuel M., Robert F. Cornell, Liping Du, et al.. (2017). Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid. 24(3). 205–211. 16 indexed citations
6.
Sethi, Tarsheen, Stacey Goodman, Samuel M. Rubinstein, et al.. (2016). Autologous Hematopoietic Cell Transplant (AHCT) Offers Prolonged Progression Free and Overall Survival in Patients with Light Chain Amyloidosis (AL) Compared with Chemotherapy Alone. Biology of Blood and Marrow Transplantation. 22(3). S233–S234. 1 indexed citations
7.
Li, Weijuan, Robert F. Cornell, Daniel J. Lenihan, et al.. (2016). Cardiovascular Complications of Novel Multiple Myeloma Treatments. Circulation. 133(9). 908–912. 34 indexed citations
8.
Lenihan, Daniel J., Sharon Phillips, Madan Jagasia, et al.. (2015). Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood. 126(23). 5363–5363. 1 indexed citations
9.
Cates, Justin, Heather A. Cole, David Slosky, et al.. (2014). Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma. Molecular Cancer Research. 12(8). 1100–1111. 43 indexed citations
10.
Groarke, John D., Toni K. Choueiri, David Slosky, Susan Cheng, & Javid J. Moslehi. (2014). Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway. Current Treatment Options in Cardiovascular Medicine. 16(9). 335–335. 29 indexed citations
11.
Young, Michael N., et al.. (2014). An Uncommon Presentation for Cardiac Melanoma. SHILAP Revista de lepidopterología. 1(3). 128–132.
12.
Ohba, Tetsuro, Justin Cates, Heather A. Cole, et al.. (2014). Pleiotropic effects of bisphosphonates on osteosarcoma. Bone. 63. 110–120. 36 indexed citations
13.
Cole, Heather A., Justin Cates, David Slosky, et al.. (2014). Bisphosphonates Inhibit Osteosarcoma-Mediated Osteolysis Via Attenuation of Tumor Expression of MCP-1 and RANKL. Journal of Bone and Mineral Research. 29(6). 1431–1445. 63 indexed citations
14.
Salloum, Joseph, Debra A. Dodd, David Slosky, & David Zhao. (2007). Treatment of Unprotected Left Main Coronary Artery Stenosis in a 5-Year-Old Heart Transplant Patient Using a Sirolimus-Eluting Stent. The Journal of Heart and Lung Transplantation. 26(10). 1061–1064. 6 indexed citations
15.
Slosky, David, Michael C. Hindman, Robert H. Peter, & Andrew G. Wallace. (1981). Effects of oral hydralazine on rest and exercise hemodynamics in patients with aortic or mitral regurgitation and left ventricular dysfunction. Clinical Cardiology. 4(4). 162–167. 2 indexed citations
16.
Hindman, Michael C., et al.. (1980). Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction.. Circulation. 61(4). 751–758. 26 indexed citations
17.
Stewart, James A., et al.. (1979). Detection of persistent left superior vena cava by two‐dimensional contrast echocardiography. Journal of Clinical Ultrasound. 7(5). 357–360. 19 indexed citations
18.
Slosky, David & James K. Todd. (1977). Diagnosis of Urinary Tract Infection. Clinical Pediatrics. 16(8). 698–701. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edelmiro Regañón Breakdown of academic impact, for papers by Virtudes Vila Breakdown of academic impact, for papers by P. Reinecke Breakdown of academic impact, for papers by Simone Mangan Breakdown of academic impact, for papers by Dìlek Dìnçol Breakdown of academic impact, for papers by Paraskevi Roussou Breakdown of academic impact, for papers by Katerina Sfiridaki Breakdown of academic impact, for papers by Weihui Shentu Breakdown of academic impact, for papers by F. Majois Breakdown of academic impact, for papers by Νικόλαος Παναγόπουλος
Rankless by CCL
2026